Events
J.P. Morgan week and WuXi Global Forum 2025 in San Francisco
13-16 January, 2025
San Francisco, CA, USA
ENYO Pharma will in San Francisco for the J.P Morgan week to reconnect with global industry leaders, emerging fast-growth companies, innovative technology creators and members of the investment community.
ENYO Pharma will also take the opportunity to host an executive roundtable at WuXi-Global-Forum-2025 on the 14th of January to share our progress in drug development with Vonafexor in kidney diseases.
4th Rare & Genetic Kidney Disease Drug Development Summit
10-12 December 2024
Boston, MA, USA
ENYO Pharma will attend for the first time the 4th Rare & Genetic Kidney Disease Drug Development Summit that will be held in Boston, USA. The event will bring together industries, academic KOLs, and patient advocacy nephrology communities to discuss acceleration of clinical advancements in orphan kidney disease populations.
ENYO Pharma will present the ongoing ALPESTRIA-1 Phase 2 clinical trial with Vonafexor in patients with Alport syndrome.
MOSAIC – the Global NASH/MASH Trialist Forum
24-25 October 2024
Washington DC, USA
ENYO Pharma is attending the MOSAIC – Global NASH Trialist Forum 2024. The goal of the meeting was to define new integrative Cardiovascular-Kidney-Liver-Metabolic (CKLM) trials together with cardiology, endocrinology & hepatology clinical trialists, industry, regulatory experts, payers, patients representatives and other stakeholders.
ASN Kidney Week 2024
23-27 October 2024
San Diego, CA
ENYO Pharma will attend the world’s premier nephrology meeting of the American Society of Nephrology, ASN Kidney Week.
https://www.asn-online.org/education/kidneyweek/2024/important-dates.aspx
Alport Connect 2024, the annual Alport syndrome patient and family meeting in US
27-28 July 2024
Denver, CA
ENYO Pharma is sponsoring and will attend Alport Connect 2024 organized by the American Alport Syndrome Foundation (ASF), the Alport syndrome patient-led non-profit organization in the US.
ENYO Pharma will meet patients and their families to present its starting Phase 2 “ALPESTRIA-1” clinical study with Vonafexor in Alport syndrome patients.
Latest Press Release 